ALA-ALA-PHE-CHLOROMETHYLKETONE TFA structure
|
Common Name | ALA-ALA-PHE-CHLOROMETHYLKETONE TFA | ||
---|---|---|---|---|
CAS Number | 102129-66-8 | Molecular Weight | 339.81700 | |
Density | 1.215g/cm3 | Boiling Point | 508.9ºC at 760 mmHg | |
Molecular Formula | C16H22ClN3O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 261.6ºC |
Use of ALA-ALA-PHE-CHLOROMETHYLKETONE TFAAAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research[1]. |
Name | (2S)-2-amino-N-[(2S)-2-[[(2S)-4-chloro-3-oxo-1-phenylbutan-2-yl]amino]propanoyl]propanamide |
---|---|
Synonym | More Synonyms |
Description | AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research[1]. |
---|---|
Related Catalog | |
In Vitro | AAF-CMK (0-20 μM; 24 h) shows potentiated antitumor effects of U937 leukemia cells in combination with TRAIL or TNF[1]. AAF-CMK (20 μM; 24 h) increases TNF- and TRAIL-induced U937 cell apoptosis[1]. Cell Viability Assay[1] Cell Line: U937 human promonocytic leukemia cells Concentration: 0-20 μM Incubation Time: 24 h Result: Resulted in the potentiation of growth inhibitory cytostatic effects of TRAIL as well as TNF. Apoptosis Analysis[1] Cell Line: U937 human promonocytic leukemia cells Concentration: 20 μM Incubation Time: 24 h Result: Increased the percentage of apoptotic cells to 55.8% in combination with TRAIL. Increased number of cells with characteristic apoptotic morphology in groups treated with AAF-CMK and both TRAIL or TNF compared to each group treated alone. |
Density | 1.215g/cm3 |
---|---|
Boiling Point | 508.9ºC at 760 mmHg |
Molecular Formula | C16H22ClN3O3 |
Molecular Weight | 339.81700 |
Flash Point | 261.6ºC |
Exact Mass | 339.13500 |
PSA | 104.78000 |
LogP | 2.30520 |
Vapour Pressure | 1.78E-10mmHg at 25°C |
Index of Refraction | 1.545 |
AAPCK |
Alanyl-alanyl-phenylalanine chloromethyl ketone |
Ala-ala-phe-chloromethyl ketone |